Epoch Investment Partners Inc. grew its position in shares of Liberty Global PLC Class A (NASDAQ:LBTYA) by 1.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,946,065 shares of the company’s s

Loxo Oncology (NASDAQ:LOXO) is scheduled to be announcing its earnings results before the market opens on Thursday, August 9th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday,

Tag Archives: XRM

The word “growth” is the central word in the phrase Dividend Growth Investing, yet DGI often gets a bad rap as a stodgy method of saving for retirement. I think this misperception arises from the fact that some proponents of the strategy (who may be more focused on income than returns) require a certain minimum yield threshold for their investments. This, in turn, screens many of the higher growth companies from their radar, as higher growth companies generally have lower payout ratios than their slower growth counterparts.

As a result, many of the same old slow-growing blue chips like Coca-Cola (NYSE:KO), Proctor & Gamble (NYSE:PG), and General Mills (NYSE:GIS) are widely held and discussed in the “Dividends” section of Seeking Alpha, while other higher growth opportunities are passed over. This is unfortunate, because there are several very high quality companies that are being disqualified simply because of a lower yield.

These lower yield, higher growth companies can be excellent investments for those with an extended time horizon, and even for retirees they can be a nice boost for a portfolio. For all the angst of wanting enough immediate income, a freshly minted retiree should realize that they are also likely looking at a 20 year time frame for their investments. As the ssa.gov life expectancy calculator shows, a male turning 62 years old in 2016 can expect to live an additional 21.6 years.

As badly as short sellers want to hate on Green Mountain Coffee Roasters (GMCR), betting against the multiyear rally in this $12.7 billion beverage stock has been about as wise as eating from a box with a skull and crossbones on it. And as a bull market continues to lift all ships, Green Mountain’s ship is going to keep floating above the others.

Green Mountain owns Keurig, the brand of beverage brewers that use self-contained K-Cups to make coffee, teas, and other drinks. While Keurig’s “fad” status has certainly helped tip the deck against GMCR, the fact remains that the firm has done most of the hard work in getting Keurig machines accepted by consumers. With brewers essentially ubiquitous at this point, the firm is able to make money on its cash cow: the K-Cups.

Keurig’s individual-serving cups have big margins and a big installed base. With huge convenience and the relatively large sunk cost that consumers have put into their Keurig machines, it’s a sticky business with big switching costs. Consumers who buy a Keurig are much less likely to spend the money on a competing brand of proprietary coffee pods.

I’ve said before that GMCR is far from cheap right now. But its momentum trajectory is showing few signs of fizzling out, especially as direct competitors such as Starbucks (SBUX) continue to sell K-Cups of their own. Don’t bet against GMCR in September – buy this Rocket Stock instead.

[By Canadian Value]

So Im going to stick my next out and share my views on four battleground stocks that are among my favorite shorts: World Acceptance (WRLD), Green Mountain (GMCR), Herbalife (HLF), and InterOil (IOC). And next week at the Value Investing Congress I will present another short, my largest.

[By David Sterman]

But for short sellers in Green Mountain Coffee Roasters (Nasdaq: GMCR), there's another outcome: They've been badly burned as shares have surged, but they insist they've been right all along, and it's only a matter of time before the stock crashes and burns.

Hot Blue Chip Stocks To Invest In 2018: Ternium S.A.(TX)

Advisors’ Opinion:

[By Matthew DiLallo]

Shares of Ternium SA (NYSE:TX) jumped on Wednesday: up more than 10% by 2:30 p.m. EST. While the steelmaker reported weaker-than-expected earnings after the closing bell yesterday, it provided optimistic guidance and announced a compelling acquisition.

Hot Blue Chip Stocks To Invest In 2018: Shire plc(SHPG)

Advisors’ Opinion:

[By Max Macaluso and David Williamson]

At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG ) and pharmaceutical giant Sanofi (NYSE: SNY ) may be circling ViroPharma (NASDAQ: VPHM ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

[By Todd Campbell]

The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

[By Jim Robertson]

That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth. From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

Hot Blue Chip Stocks To Invest In 2018: Pound/Rand(PX)

Advisors’ Opinion:

[By Ben Levisohn]

The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:

In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…

Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).

Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.

Hot Blue Chip Stocks To Invest In 2018: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

[By kiplinger]

52-week high: $18.93

52-week low: $11.01

Annual revenues: $492.9 million

Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.

Organovo Holdings Inc. (NASDAQ: ONVO) shares saw a handy gain on Tuesday after the bio-printer announced that it received a strong consumer response from its second tissue service. Specifically, the ExVive Human Kidney Tissue launched in September, which uses Organovos 3D bio-printed kidney tissue to study the effects of drug exposure through toxicology panels and transporter studies.

The company already has multiple commercial orders from several customers, including with two global, top 25 pharmaceutical companies.

For some background: Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.

Top 10 Medical Stocks For 2018: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

[By kiplinger]

52-week high: $18.93

52-week low: $11.01

Annual revenues: $492.9 million

Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.

Scripps Networks Interactive (SNI) sunk to the bottom of the S&P 500–narrowly beating out Apartment Investment and Management (AIV)–as the parent company of the Food Network and other channels gave back a chunk of its post-elections gains.

[By Ben Levisohn]

Apartment Investment & Management (AIV) tumbled today, as the weakness in real-estate investment trusts following Donald Trump’s surprise election continued today. It was the second-biggest loser in the S&P 500 today.

In a note released yesterday, Raymond James analyst Buck Horne and team cut their price target on Apartment Investment & Management to $50 from $50, even as they maintained their Strong Buy rating. They explain why:

Apartment Investment & Management reported net income of $67 million on sales of $978 million in 2015.

Top 10 Medical Stocks For 2018: region(DGLD)

Advisors’ Opinion:

[By Jim Robertson]

The VelocityShares 3x Inverse Gold ETN (NASDAQ: DGLD) seeks to provideshort exposure to three times (3x) the daily performance of theS&P GSCI Gold Index. As with UGLD, DGLD would be doing this viafutures contracts.

Top 10 Medical Stocks For 2018: Golden Star Resources Ltd(GSS)

Advisors’ Opinion:

[By Cameron Saucier]

Golden Star (NYSEMKT: GSS) is a gold mining and exploration company, and operates gold mines in Ghana, West Africa. GSS is up 396% YTD after it announced in July that it had begun pre-commercial production of gold in an underground mine in Ghana. GSS is trading at $0.825 per share on Monday intraday.

Top 10 Medical Stocks For 2018: Clean Diesel Technologies Inc.(CDTI)

Advisors’ Opinion:

[By Monica Gerson]

Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

Sphere 3D Corp. (NASDAQ: ANY) is estimated to post a quarterly loss at $0.11 per share on revenue of $22.10 million.

Top 10 Medical Stocks For 2018: AltaGas Ltd. (ATGFF)

Advisors’ Opinion:

[By SEEKINGALPHA.COM]

AltaGas (OTCPK:ATGFF) recently announced that it’s going to acquire WGL Holdings (NYSE:WGL). This article will examine the financial side of the transaction. A number of Seeking Alpha authors have written articles on the merger as well, and I suggest that you read them.

[By SEEKINGALPHA.COM]

Regulators in California are behind a new business of providing utility-scale back-up battery storage at power generating facilities. Canadian-based AltaGas (OTCPK:ATGFF) recently announced a 10-year Energy Storage Resource Adequacy Purchase Agreement with Southern California Edison SCE, a subsidiary of Edison International (NYSE:EIX). A recap of the scope of the contract is described below, from ATGFF’s press release:

Top 10 Medical Stocks For 2018: YPF Sociedad Anonima(YPF)

These are the top 5 holdings of Knighthead Capital Management, LLCSPDR S&P 500 (SPY) – 1,500,000 shares, 57.03% of the total portfolio. Spirit Realty Capital Inc (SRC) – 9,113,000 shares, 11.82% of the total portfolio. New PositionYPF SA (YPF) – 2,153,795 shares, 7.26% of the total portfolio. Shares reduced by 1.5%TerraForm Global Inc (GLBL) – 9,200,000 shares, 6.61% of the total portfolio. EQT Corp (EQT) – 597,300 shares, 5.9% of the total p

Top 10 Medical Stocks For 2018: Clarke(t)

Advisors’ Opinion:

[By JJ Kinahan]

Shares of AT&T Inc. (NYSE: T) were moderately lower while shares of Time Warner Inc (NYSE: TWX) headed to the upside in early trading today. Late yesterday, the Department of Justice (DoJ) surprised market observers by filing an antitrust lawsuit to block T’s $85.4 billion takeover of TWX. In the complaint, DoJ said the merger would harm competition, stifle innovation and drive up prices.

[By Laurie Kulikowski]

Net operating cash flow has increased to $10,797.00 million or 23.76% when compared to the same quarter last year. In addition, AT&T INC has also modestly surpassed the industry average cash flow growth rate of 16.21%.

The gross profit margin for AT&T INC is rather high; currently it is at 55.43%. Regardless of T’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.65% trails the industry average.

[By Chris Lange]

24/7 Wall St. took a peek at plans from Verizon Communications Inc. (NYSE: VZ), AT&T Inc. (NYSE: T), T-Mobile US Inc. (NASDAQ: TMUS) and Sprint Corp. (NYSE: S). We have also provided some of the key highlights from each plan. In a separate post we looked at which companies offer the best service.

[By WWW.MONEYSHOW.COM]

With a dividend yield of 4.8%, AT&T (T) will continue to be an attractive income investment whether or not the merger with Time Warner (TWX) happens. AT&T recently completed other deals that have increased earnings and strengthened dividend safety.

Top 10 Medical Stocks For 2018: New Residential Investment Corp.(NRZ)

Advisors’ Opinion:

[By ]

New Residential (NYSE: NRZ) is a U.S.-based REIT that specializes in managing investments in residential real estate. With a market cap of $5.5 billion, NRZ is one of the largest REITs in the United States, so this is no fly-by-night company. NRZ offers one of the best dividends in the industry. The trust made four dividend payments in 2017 totaling $1.94. That gives shares a current yield of 11.3%, more than a 400% premium to the S&P 500’s average 2.0% yield.

[By Lisa Levin]

Ocwen Financial Corp (NYSE: OCN) shares were also up, gaining 42 percent to $3.25. New Residential Investment Corp (NYSE: NRZ) revealed it owned some servicing rights to the troubled Ocwen Financial. During today's conference call, New Residential’s executive suggested the company will pay $425 million for Mortgage Servicing Rights to Ocwen.

[By Sean Williams]

Today’s lawsuit has spilled over to the company’s peers as well. New Residential Investment Corp. (NYSE:NRZ), which invests in excess mortgage servicing rights (MSRs), wound up falling as much as 13% during the day’s trading session. Ocwen is one of the three companies mentioned as being one of the primary servicers in New Residential Investment’s MSRs, according to its 10-K. If mortgage owners or bondholders terminate Ocwen as the servicer, the excess MSRs tied to Ocwen could lose some or all of their value.Altisource Portfolio Solutions S.A.(NASDAQ: ASPS)fell 42%.

[By Chris Dier-Scalise]

Thge Vetr crowd upgraded its rating for New Residential Investment Corp (NYSE: NRZ) on Friday from the company's previous standing at 3 stars (Hold), issued 10 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Top 10 Medical Stocks For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

[By Lisa Levin]

Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

[By Lisa Levin]

Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

This is an update of my preceding article on North Atlantic Drilling(NYSE:NADL), published on May 30, 2016, about the 1Q’16 results.

Click to enlargeThe West Phoenix – Courtesy of NADL.

NADL conference call transcript from Seeking Alpha. Click here.

Complete Fleet Analysis as of August 25, 2016

Here’s an overview of the fleet status:

# Name

Type

stock market day trading: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

[By kiplinger]

52-week high: $18.93

52-week low: $11.01

Annual revenues: $492.9 million

Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.

stock market day trading: Hostess Brands, Inc. (TWNK)

Advisors’ Opinion:

[By Paul Ausick]

There was an IPO of sorts last week when Gores Holdings II raised $375 million with an offer of 37.5 million units at $10 per unit. The shares are listed on the Nasdaq under the ticker symbol GSHTU. Gores Holdings I acquired Hostess Brands last year and completed an IPO in December for Hostess Brands Inc. (NASDAQ: TWNK).

stock market day trading: LinkedIn Corporation(LNKD)

Advisors’ Opinion:

[By Andres Cardenal]

The most powerful investment ideas are the ones that can be easily explained and understood. LinkedIn(LNKD) is an undisputed market leader in remarkably promising areas such as professional networking and online employment opportunities, and this makes the company a top name to buy in 2016 and hold for years to come.

As of the third quarter of 2015, LinkedIn(LNKD) had 396 million registered members around the world, a big increase of 20% versus the same quarter the previous year, and 39,726 corporate solutions customers on the platform, a year-over-year increase of 31%. Individuals and corporations attract each other to LinkedIn in search of opportunities, and this creates a virtuous cycle driving sustainable growth over the long term.

Management is also translating the company’s massive opportunities into rapid revenue growth. Total sales grew 37% to $780 million last quarter, with the acquisition of online learning platform lynda.com representing $41 million of that. LinkedIn’s three growth engines are firing on all cylinders: Talent solutions for corporations grew 46%, while premium subscription sales increased 21%, and online advertising revenue jumped 28%.

LinkedIn(LNKD) is actively investing for growth, so profit margins are hard to predict in the short term. However, the company should be able to combine solid revenue growth and expanding profit margins in the years ahead.

[By Alex McGuire]

For example, LinkedIn Corp. (NYSE: LNKD) fell 16.1% to $79.03 from its IPO date on May 19, 2011, to Aug. 19, 2011. But LNKD stock has since recovered 148% to today’s share price of $195.96.

[By Benzinga News Desk]

Microsoft has offered concessions to EU antitrust regulators over its $26.2 billion, $196 per share offer for LinkedIn (NYSE: LNKD), according to the European Commission. The EU regulator had expressed concerns to Microsoft executives about the deal, which was announced in June.

stock market day trading: QCR Holdings Inc.(QCRH)

Advisors’ Opinion:

[By Keith Fitz-Gerald]

My favorite at the moment is QCR Holdings Inc. (NasdaqGM:QCRH).

Founded in 1993 and headquartered in Moline, IL, the bank has a strong regional lending base in Illinois and Iowa that should grow in line with the broader national economy. I particularly like the fact that the bank considers itself relationship-driven at a time when trust is in short supply.

Executives at Deutsche Bank AG are contemplating dramatic options for the German lender, including selling all or part of a key business, a sign of growing pressure to speed up a flagging overhaul.

This weekend, senior executives are meeting to debate some of these options, according to people familiar with the plans. One has already been floated: a merger with Germany’s second-largest bank by market value, Commerzbank AG, the people said. Deutsche Bank and Commerzbank held preliminary discussions about a tie-up in August, before concluding last week it wasn’t viable.

Chief Executive John Cryan, who was named co-CEO in July 2015, has set out a long-term plan of shrinking Deutsche Bank and cutting costs. But the merger discussions and the weekend summit signify that the bank may not have the luxury of a drawn-out revamp. On Wednesday, Mr. Cryan found himself on stage at a financial conference in Frankfurt batting back speculation about a merger.

Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

[By Keith Speights]

Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

Top 5 Value Stocks To Own For 2018: Navigant Consulting, Inc.(NCI)

Advisors’ Opinion:

[By Lisa Levin]

Shares of Navigant Consulting, Inc. (NYSE: NCI) were down 14 percent to $17.02 after the company posted downbeat quarterly results.

Top 5 Value Stocks To Own For 2018: Cal-Maine Foods, Inc.(CALM)

Wall Street expects Rite Aid Corporation (NYSE: RAD) to report quarterly earnings at $0.04 per share on revenue of $8.23 billion before the opening bell. Rite Aid shares gained 0.83 percent to $8.54 in after-hours trading.
Micron Technology, Inc. (NASDAQ: MU) reported better-than-expected profit for its first quarter and issued a strong forecast for the current quarter. Micron shares climbed 9.91 percent to $22.62 in the after-hours trading session.
Analysts expect Cal-Maine Foods Inc (NASDAQ: CALM) to post quarterly earnings at $0.48 per share on revenue of $262.83 million after the closing bell. Cal-Maine shares rose 0.12 percent to $42.75 in after-hours trading.
Red Hat Inc (NYSE: RHT) reported upbeat earnings for its third quarter, but sales missed expectations. The company also announced that its CFO Frank Calderoni is stepping down. Red Hat shares tumbled 10.15 percent to $71.69 in the after-hours trading session.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

[By Tyler Crowe, Jordan Wathen, and Beth McKenna]

So we asked three of our contributors to highlight a stock they see as a real underdog in the market today and why investors should be watching this stock. Here’s a quick look into why they picked banker Wells Fargo (NYSE:WFC), railcar manufacturer Greenbrier Companies (NYSE:GBX) , and egg wholesaler Cal-Maine Foods (NASDAQ:CALM)

[By Craig Jones]

On CNBC's Fast Money Halftime Report, Jon Najarian said that Cal-Maine Foods Inc (NASDAQ: CALM) had unusually high options volume on Friday. Traders were buying the May 45 calls and Jon Najarian decided to follow the trade. He is planning to hold the position for 1 to 2 months.

Top 5 Value Stocks To Own For 2018: Marvell Technology Group Ltd.(MRVL)

Advisors’ Opinion:

[By Lisa Levin]

Marvell Technology Group Ltd. (NASDAQ: MRVL) shares shot up 10 percent to $14.70 after the company reported upbeat Q3 results and announced a $1 billion share buyback.

[By Chris Lange]

When Marvell Technology Group Ltd. (NASDAQ: MRVL) released its fiscal third-quarter results after the markets closed on Tuesday, it posted $0.34 in earnings per share (EPS) and $616.3 million in revenue. Consensus estimates had called for $0.33 in EPS on revenue of $613.1 million. The same period of last year reportedly had EPS of $0.21 and $604.75 million in revenue.

[By Lisa Levin]

Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday’s regular session.

Top 5 Value Stocks To Own For 2018: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

[By kiplinger]

52-week high: $18.93

52-week low: $11.01

Annual revenues: $492.9 million

Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.